Cosmetic Grade:
1. VP/VA37E(liquid) 2. VP/VA55E(liquid) 3. VP/VA55W(liquid) 4. VP/VA64E(liquid) 5. VP/VA64S 6. VP/VA64W(liquid) 7. VP/VA73E(liquid)
8. VP/VA73W(liquid)
Pharmaceutical Grade(USP/EP/BP) :
1. VA64(Powder) 2. Heavy metals ppm
*The following content is generated by AI and is for reference only.
PVP-A Copolymer Series, commercially known as Copovidone, represents a significant advancement in pharmaceutical excipient technology. It is a water-soluble copolymer synthesized through the free radical polymerization of vinylpyrrolidone and vinyl acetate monomers. The resulting molecular structure typically follows the formula (C₆H₉NO)ₓ(C₄H₆O₂)ᵧ, where the ratio of components varies slightly depending on the specific grade within the series. Its primary CAS number is 9003-39-8, though specific batch variations may carry distinct identifiers for regulatory tracking.
This versatile material serves as a critical binder, disintegrant, and solubility enhancer in modern drug formulation. Unlike traditional polyvinylpyrrolidone (PVP), Copovidone exhibits superior stability under varying pH conditions and demonstrates exceptional resistance to hydrolysis, ensuring consistent performance during long-term storage. A defining characteristic of this copolymer is its ability to form stable amorphous solid dispersions. By inhibiting the crystallization of poorly soluble active pharmaceutical ingredients (APIs), it significantly enhances bioavailability, making it indispensable for developing next-generation formulations with low water solubility.
In tablet manufacturing, PVP-A Copolymer acts as an effective granulating agent, providing robust mechanical strength without compromising dissolution rates. Furthermore, its film-forming properties make it suitable for coating applications, protecting sensitive drugs from moisture and light degradation. The copolymer is generally recognized as safe (GRAS) by major regulatory bodies, including the FDA and EMA, facilitating global market approval. Its compatibility with a wide range of excipients allows formulators to optimize dosage forms ranging from immediate-release tablets to sustained-release systems. As the pharmaceutical industry increasingly focuses on complex molecules and biotechnology products, Copovidone remains a cornerstone excipient, bridging the gap between chemical stability and therapeutic efficacy. Its unique balance of viscosity, binding power, and solubility enhancement capabilities ensures its continued dominance in quality drug development pipelines worldwide.